AI Article Synopsis
Article Abstract
Cardiac KCNQ1/KCNE1 channels (IKs) are dependent on the concentration of membrane phosphatidylinositol-4,5-bisphosphate (PIP2) and on cytosolic ATP by two distinct mechanisms. In this study we measured IKs and FRET between PH-PLCδ-based fluorescent PIP2 sensors in a stable KCNQ1/KCNE1 CHO cell line. Effects of activating either a muscarinic M3 receptor or the switchable phosphatase Ci-VSP on IKs were analyzed. Recovery of IKs from inhibition induced by muscarinic stimulation was incomplete despite full PIP2 resynthesis. Recovery of IKs was completely suppressed under ATP-free conditions, but partially restored by the ATP analog AMP-PCP, providing evidence that depletion of intracellular ATP inhibits IKs independent of PIP2-depletion. Simultaneous patch-clamp and FRET measurements in cells co-expressing Ci-VSP and the PIP2-FRET sensor revealed a component of IKs inhibition directly related to dynamic PIP2-depletion. A second component of inhibition was independent of acute changes in PIP2 and could be mimicked by ATP-free pipette solution, suggesting that it results from intracellular ATP-depletion. The reduction of intracellular ATP upon Ci-VSP activation appears to be independent of its activity as a phosphoinositide phosphatase. Our data demonstrate that ATP-depletion slowed IKs activation but had no short-term effect on PIP2 regeneration, suggesting that impaired PIP2-resynthesis cannot account for the rapid IKs inhibition by ATP-depletion. Furthermore, the second component of IKs inhibition by Ci-VSP was reduced by AMP-PCP in the pipette filling solution, indicating that direct binding of ATP to the KCNQ1/KCNE1 complex is required for voltage activation of IKs. We suggest that fluctuations of the cellular metabolic state regulate IKs in parallel with Gq-coupled PLC activation and PIP2-depletion.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cellsig.2015.04.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concentration-QTcF analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia.
Clin Transl Sci
November 2024
Quantitative Clinical Pharmacology Department, Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.
Article Synopsis
- Quizartinib extends the QT interval by inhibiting a specific potassium current, and its effects were studied in newly diagnosed acute myeloid leukemia (AML) patients using complex modeling techniques during a clinical trial.
- The research evaluated how quizartinib and its metabolite AC886 impact the Fridericia-corrected QT interval (QTcF) using multiple measurements and various modeling approaches, identifying factors like age and hypokalaemia as relevant.
- Results showed a significant non-linear increase in QTcF with higher quizartinib doses, supporting the need for dosage adjustments in patients, especially when combined with certain other medications.
Dual effects of mefenamic acid on the I molecular complex.
Br J Pharmacol
November 2024
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada.
Article Synopsis
- - Mefenamic acid, a non-steroidal anti-inflammatory drug, can both enhance and inhibit cardiac ion currents formed by KCNQ1 and KCNE1 channels, revealing its dual effect on these channels, especially in patients with long and short QT syndromes.
- - The study used whole cell patch clamp techniques and molecular dynamics simulations to investigate how mefenamic acid interacts with these channels, particularly noting its inhibition at high concentrations and its potential to preserve some current potentiation effects.
- - Findings emphasize the importance of specific structural regions in the KCNQ1/KCNE1 channels that influence how drugs like mefenamic acid affect ion current, which has significant implications for developing treatments for certain genetic long QT syndrome mutations.*
Evaluating the proarrhythmic risk of delayed-action compounds in serum free cell culture conditions; serum-starvation accelerates/amplifies the effect of probucol on the KCNQ1 + KCNE1 channel.
J Pharmacol Toxicol Methods
December 2024
Department of Basic and Applied Medical Sciences, Faculty of Medicine, Ghent University, 9000 Ghent, Belgium. Electronic address:
In vitro testing procedures for evaluating acute effects of compound on ion channels, utilizing heterologous expression systems (HES), are well-established, while slowly manifesting delayed effects remain challenging to detect. For this, immortalized HES are exposed to the compounds for a longer time, in general 24 h. As these cells proliferate every 12-20 h, we evaluated if the proliferation status, and by extension cell metabolism, influences the delayed compound response.
View Article and Find Full Text PDFNuciferine analogs block voltage-gated sodium, calcium and potassium channels to regulate the action potential and treat arrhythmia.
Biomed Pharmacother
October 2024
Key Laboratory of External Drug Delivery System and Preparation Technology in Universities of Yunnan and Faculty of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming, Yunnan, China; State Key Laboratory of Chemical Biology and Drug Discovery and Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, China. Electronic address:
Article Synopsis
- - Dysfunction in Nav1.5, Cav1.2, and Kv ion channels can lead to serious heart conditions like arrhythmias and heart failure, prompting research into new treatments.
- - A novel compound, identified as 6a, effectively blocks specific ion currents and alters the behavior of Nav and Cav channels, showing significant potential for treating heart rhythm disorders without major side effects.
- - In animal studies, 6a demonstrated the ability to reduce arrhythmia duration and normalize heart activity, suggesting that nuciferine analogs could be developed into effective antiarrhythmic medications.
Bayesian approach enabled objective comparison of multiple human iPSC-derived Cardiomyocytes' Proarrhythmia sensitivities.
J Pharmacol Toxicol Methods
July 2024
Consortium for Safety Assessment Using Human iPS Cells (CSAHi), HEART Team, Tokyo, Japan; Daiichi Sankyo RD Novare Co., Ltd., Tokyo 134-8630, Japan; Axcelead Drug Discovery Partners, Inc., Kanagawa 251-0012, Japan.
The one-size-fits-all approach has been the mainstream in medicine, and the well-defined standards support the development of safe and effective therapies for many years. Advancing technologies, however, enabled precision medicine to treat a targeted patient population (e.g.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!